samedan logo

 
 
spacer
home > pmps > winter 2021 > vaccine logistics: deep-freeze storage in container design
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Vaccine Logistics: Deep-Freeze Storage in Container Design

How Do You Transport and Store Vaccines Reliably at Temperatures of -70°C to -80°C?

L&R Kältetechnik has developed a coherent, efficient, and innovative concept for this challenge: a deepfreeze storage system that is installed in an industrial container. The basis for the development is the comprehensive knowledge L&R has acquired for the planning and manufacturing of sophisticated (deep) freeze systems and ultra-low temperature storage systems for pharmaceutical production.

Originally, the ‘core business’ for L&R Kältetechnik in the pharma industry was to provide the low temperatures required for production. Many production sites all over Europe are equipped with L&R cooling systems that can reach a cooling capacity in the megawatt (MW) range, and are absolutely fail-safe thanks to redundant refrigerating circuits.

Process Cooling For Pharma Production – Even in a Multi-Megawatt Range

One current example: L&R planned and installed a large cooling facility providing low temperatures on two levels of -15°C and -25°C for a manufacturer of medicines for the treatment of blood diseases such as haemophilia – and on a large scale at that. A total of five ultra-low temperature systems with 12 refrigerating circuits and a total cooling capacity of 2.35MW generate the required process cooling.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
L&R Kältetechnik GmbH & Co.

KG Hachenerstrasse 90a-c 59846 Sundern

www.lr-kaelte.de

E: info@lr-kaelte.de

Read more on L&R’s mobile pharma storage: https://bit. ly/3adrqfN
Print this page
Send to a friend
Privacy statement
News and Press Releases

Theravectys Announces $20M Funding Round

THERAVECTYS, the world leading pioneer in lentiviral vector technology, announced today a fully subscribed $20M funding round. This funding will be used to progress the Theravectys pipeline by driving several vaccine candidates, including their COVID vaccine, into phase 1 and 1-2 clinical trials.
More info >>

White Papers

Another Successful Visit Against the Odds

Medical Research Network (MRN) Limited

Our dedicated team of nurses, couriers and project managers deliver, come rain or shine. Making sure a Clinical Trial visit can go ahead in the home can be a complex process, and last month bad weather nearly stopped play on an important Home Trial Support visit. Thanks to the commitment and dedication from the entire team it went ahead against the odds.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement